智通财经网·2025-08-26 16:59Core Viewpoint - Junshi Biosciences (688180.SH) reported a significant revenue increase of 48.64% year-on-year for the first half of 2025, driven by the sales of commercialized drugs, despite a net loss attributable to shareholders of 413 million yuan [1] Financial Performance - The company achieved a revenue of 1.168 billion yuan, an increase of approximately 382 million yuan compared to the same period last year, reflecting a growth rate of 48.64% [1] - The net loss attributable to shareholders was 413 million yuan, with a basic earnings per share of -0.42 yuan [1] - The adjusted net loss was 478 million yuan, indicating a reduction in losses compared to the previous year [1] Sales Performance - The sales revenue of Tuoyi® in the domestic market reached 954 million yuan, representing a year-on-year growth of approximately 42% [1] Strategic Initiatives - The company is implementing the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan, focusing on more competitive and innovative R&D projects [1] - Efforts are being made to accelerate clinical development, reduce production costs, and enhance sales efficiency to minimize losses [1]